AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38011967 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple text messages (TM+)
Number of subjects: 200
Study 38011967 — intervention group
Group type: COMPARATOR
Intervention: TM1-Continued (no further TM)
Number of subjects: 200
Study 38011967 — intervention group
Group type: EXPERIMENTAL
Intervention: TM1 & MAPS (no further TM, up to 2 MAPS calls)
Number of subjects: 200
Study 38011967 — intervention group
Group type: COMPARATOR
Intervention: TM+Continued (monthly text messages)
Number of subjects: 200
Study 38011967 — intervention group
Group type: EXPERIMENTAL
Intervention: TM+ & MAPS (monthly text messages, plus up to 2 MAPS calls)
Number of subjects: 200
Study 38011984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised 3% hypertonic saline (5 mL, three times a day)
Number of subjects: 140
Study 38011984 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (5 mL, three times a day)
Number of subjects: 140
Study 38011992 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital rule-out of NSTE-ACS using HEAR score and point-of-care troponin measurement
Number of subjects: 863
Study 38011991 — intervention group
Group type: EXPERIMENTAL
Intervention: Type-1 CMD (INOCA)
Number of subjects: 35
Study 38011991 — intervention group
Group type: COMPARATOR
Intervention: Type-4 CMD (CCS/PCI)
Number of subjects: 35
Study 38012044 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation intervention
Number of subjects: 90
Study 38012285 — intervention group
Group type: EXPERIMENTAL
Intervention: gosuranemab low-dose (125 mg q4w)
Number of subjects: 654
Study 38012285 — intervention group
Group type: EXPERIMENTAL
Intervention: gosuranemab intermediate-dose (600 mg q4w)
Number of subjects: 654
Study 38012285 — intervention group
Group type: EXPERIMENTAL
Intervention: gosuranemab high-dose (2000 mg q4w)
Number of subjects: 654
Study 38012285 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 654
Study 38012285 — intervention group
Group type: EXPERIMENTAL
Intervention: gosuranemab (all doses)
Number of subjects: 654
Study 38012327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk management for 12 months
Number of subjects: 50
Study 38012345 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphasic exercise prehabilitation intervention
Number of subjects: 0
Study 38012413 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet (n=122)
Number of subjects: 244
Study 38012450 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-encapsulated pancreatic precursor cells derived from human embryonic stem cells, 2-3-fold higher cell doses, optimized membrane perforation pattern.
Number of subjects: 10
Study 38012450 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) and insulin dosing.
Number of subjects: 10
Study 38012534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept (starting dose 0.3 mg/kg; target dose 0.7 mg/kg)
Number of subjects: 162
Study 38012534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 38012573 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) + Motivational Interviewing (MI) for AUD group
Number of subjects: 242
Study 38012573 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) for all patients
Number of subjects: 242
Study 38012573 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) for non-AUD group
Number of subjects: 242
Study 38012644 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash transfers (10,000 KES, ~$75 USD/month) and personalized infant feeding support from pregnancy to 7 months postpartum
Number of subjects: 40
Study 38012644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 38012647 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA)
Number of subjects: 3290
Study 38012647 — intervention group
Group type: COMPARATOR
Intervention: Usual procedures (Control)
Number of subjects: 3290
Study 38012647 — intervention group
Group type: EXPERIMENTAL
Intervention: SAIA (adjusted for provider training)
Number of subjects: 3290
Study 38012682 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine and ATRA (all-trans retinoic acid) combination therapy administered over 52 cycles
Number of subjects: 1
Study 38012731 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position in early ARDS
Number of subjects: 57
Study 38012731 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position in persistent ARDS
Number of subjects: 57
Study 38012740 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation training utilizing key identification technology for movement
Number of subjects: 104
Study 38012740 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercises in a hospital setting
Number of subjects: 104
Study 38012751 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA vaccines
Number of subjects: 0
Study 38012776 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference-based adapted physical activity combined with endometriosis-based education program (6-month program, 45-120 min/week)
Number of subjects: 200
Study 38012776 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference-based adapted physical activity combined with endometriosis-based education program
Number of subjects: 200
Study 38012776 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 200
Study 38012795 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of amisulpride (100 mg)
Number of subjects: 120
Study 38012820 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-ECG analysis algorithm
Number of subjects: 9000
Study 38012835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 7.2 mg
Number of subjects: 35
Study 38012862 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE candidates (D + kidneys)
Number of subjects: 324
Study 38012862 — intervention group
Group type: COMPARATOR
Intervention: Non-HOPE candidates (not listed for D + kidneys)
Number of subjects: 324
Study 38012862 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE candidates
Number of subjects: 324
Study 38012862 — intervention group
Group type: COMPARATOR
Intervention: Non-HOPE candidates
Number of subjects: 324
Study 38012899 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green-near-infrared fluorescence imaging
Number of subjects: 42
Study 38012959 — intervention group
Group type: COMPARATOR
Intervention: 4vHPV types
Number of subjects: 1871
Study 38012959 — intervention group
Group type: COMPARATOR
Intervention: 9vHPV types
Number of subjects: 1871
Study 38012959 — intervention group
Group type: COMPARATOR
Intervention: Cumulative IP incidence over 36 months (excluding anal canal; any 9vHPV type)
Number of subjects: 1871
Study 38012987 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms in the second trimester (Edinburgh Postnatal Depression Scale score of ≥10)
Number of subjects: 301
Study 38012987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained first- and second-trimester depressive symptoms
Number of subjects: 301
Study 38012987 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-trimester depressive symptoms in pregnancies with male fetuses
Number of subjects: 301
Study 38012987 — intervention group
Group type: COMPARATOR
Intervention: First trimester depressive symptoms
Number of subjects: 301
Study 38012987 — intervention group
Group type: COMPARATOR
Intervention: Third trimester depressive symptoms
Number of subjects: 301
Study 38013135 — intervention group
Group type: EXPERIMENTAL
Intervention: Completely oral anticoagulation
Number of subjects: 5158
Study 38013135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential anticoagulation with DOACs
Number of subjects: 5158
Study 38013135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential anticoagulation with VKAs
Number of subjects: 5158
Study 38013135 — intervention group
Group type: EXPERIMENTAL
Intervention: Completely parenteral anticoagulation
Number of subjects: 5158
Study 38013135 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis with DOACs
Number of subjects: 5158
Study 38013135 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant treatment
Number of subjects: 5158
Study 38013139 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 38013139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38013387 — intervention group
Group type: EXPERIMENTAL
Intervention: Managers
Number of subjects: 10820
Study 38013387 — intervention group
Group type: COMPARATOR
Intervention: Employees
Number of subjects: 10820
Study 38013387 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 10820
Study 38013387 — intervention group
Group type: EXPERIMENTAL
Intervention: Managerial position
Number of subjects: 10820
Study 38013523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (2 days fasting, 5 days ad libitum diet per week)
Number of subjects: 140
Study 38013523 — intervention group
Group type: COMPARATOR
Intervention: Usual healthy lifestyle (control group)
Number of subjects: 140
Study 38013593 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusions
Number of subjects: 305
Study 38013593 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloantibodies detection
Number of subjects: 305
Study 38013593 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusions over decades
Number of subjects: 305
Study 38013594 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB and MenACWY vaccines (two doses, given 1 month apart)
Number of subjects: 40
Study 38014146 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMA subretinal neurostimulation system
Number of subjects: 5
Study 38014462 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Observable Anxiety Sensitivity Treatment (BOAST) - a single clinician-led intervention session followed by a two-week ecological momentary intervention (EMI) via mobile app.
Number of subjects: 0
Study 38014462 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 38014479 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) and coordinated intervention including recommendations on polypharmacy, delirium, falls, nutrition, physical exercise, and a discharge plan
Number of subjects: 821
Study 38014479 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) and coordinated intervention
Number of subjects: 821
Study 38014479 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 821
Study 38014659 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% once daily
Number of subjects: 0
Study 38014673 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 1394
Study 38014673 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 1394
Study 38014676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical circulatory support (MCS) with Impella
Number of subjects: 406
Study 38014691 — intervention group
Group type: EXPERIMENTAL
Intervention: High autoantibody concentrations targeting complement factor C3a receptor
Number of subjects: 491
Study 38014691 — intervention group
Group type: EXPERIMENTAL
Intervention: High autoantibody concentrations targeting vascular endothelial growth factor receptor-2
Number of subjects: 491
Study 38014691 — intervention group
Group type: EXPERIMENTAL
Intervention: High autoantibody concentrations targeting vascular endothelial growth factor B
Number of subjects: 491
Study 38014691 — intervention group
Group type: EXPERIMENTAL
Intervention: High autoantibody levels
Number of subjects: 491
Study 38014699 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week community-informed virtual world-based cardiac rehabilitation program
Number of subjects: 150
Study 38014699 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 38014779 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study 38015039 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Ga-FAPI-04 PET/CT
Number of subjects: 25
Study 38015219 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail (usual care plus educational materials and a mailed self-sampling kit)
Number of subjects: 31355
Study 38015219 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-in (usual care plus educational materials and the option to request a kit)
Number of subjects: 31355
Study 38015219 — intervention group
Group type: COMPARATOR
Intervention: Education (usual care plus educational materials)
Number of subjects: 31355
Study 38015220 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab (240 mg) plus gemcitabine-cisplatin
Number of subjects: 289
Study 38015220 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine-cisplatin
Number of subjects: 289
Study 38015244 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptible (S) group
Number of subjects: 30
Study 38015244 — intervention group
Group type: COMPARATOR
Intervention: Non-susceptible (NS) group
Number of subjects: 30
Study 38015244 — intervention group
Group type: COMPARATOR
Intervention: Habituating (H) group
Number of subjects: 30
Study 38015366 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosan Cabin C1 treatment (8 sessions over 9 weeks)
Number of subjects: 192
Study 38015442 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 301
Study 38015442 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 301
Study 38015467 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg
Number of subjects: 11
Study 38015467 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg
Number of subjects: 11
Study 38015467 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 11
Study 38015591 — intervention group
Group type: EXPERIMENTAL
Intervention: Inherited thrombophilia cohort
Number of subjects: 241
Study 38015591 — intervention group
Group type: COMPARATOR
Intervention: Population-based cohort (PREVHEP-ETHON study)
Number of subjects: 241
Study 38015591 — intervention group
Group type: COMPARATOR
Intervention: Comparison of cohorts
Number of subjects: 241
Study 38015598 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch-smartphone dyad for AF detection (Pulsewatch system) plus an electrocardiogram patch
Number of subjects: 120
Study 38015598 — intervention group
Group type: COMPARATOR
Intervention: Electrocardiogram patch alone
Number of subjects: 120
Study 38015602 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 4 (using frequent responder indicator)
Number of subjects: 112
Study 38015602 — intervention group
Group type: EXPERIMENTAL
Intervention: Model using events data and VFRs' previous experience (without demographic data)
Number of subjects: 112
Study 38015602 — intervention group
Group type: EXPERIMENTAL
Intervention: Model using events data only
Number of subjects: 112
Study 38015602 — intervention group
Group type: EXPERIMENTAL
Intervention: J48 decision tree algorithm
Number of subjects: 112
Study 38015658 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 750
Study 38015658 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 750
Study 38015745 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC high-risk patients (n=717, 75.3%)
Number of subjects: 952
Study 38015745 — intervention group
Group type: EXPERIMENTAL
Intervention: CSRS categories
Number of subjects: 952
Study 38015745 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall management of syncope in ED
Number of subjects: 952
Study 38015833 — intervention group
Group type: EXPERIMENTAL
Intervention: POC-PCR (The Biofire FilmArray Pneumonia Panel plus added to standard care)
Number of subjects: 294
Study 38015833 — intervention group
Group type: EXPERIMENTAL
Intervention: POC-PCR
Number of subjects: 294
Study 38015833 — intervention group
Group type: COMPARATOR
Intervention: SCO (standard care only)
Number of subjects: 294
Study 38015877 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (control)
Number of subjects: 160
Study 38015877 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking plate (LP)
Number of subjects: 160
Study 38015877 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty (HA)
Number of subjects: 160
Study 38015901 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based club intervention
Number of subjects: 222
Study 38016021 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2-Omi.BA.4/BA.5 (30-µg second booster)
Number of subjects: 727
Study 38016085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 38016085 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 38016127 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortoiliac stenosis (TASC A/B)
Number of subjects: 655
Study 38016127 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortoiliac stenosis (TASC C/D)
Number of subjects: 655
Study 38016127 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortoiliac stenosis
Number of subjects: 655
Study 38016160 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-ART treatment
Number of subjects: 152
Study 38016160 — intervention group
Group type: COMPARATOR
Intervention: ART-only group
Number of subjects: 152
Study 38016322 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted protein vaccine (5, 15 or 45 μg)
Number of subjects: 76
Study 38016322 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA vaccine (10, 20, or 50 μg)
Number of subjects: 76
Study 38016322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 76
Study 38016431 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (median logMAR 0.18, IQR 0.06-0.26)
Number of subjects: 30
Study 38016431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-luminance visual acuity (LLVA) (median logMAR 0.66, IQR 0.36-0.88)
Number of subjects: 30
Study 38016431 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry mean sensitivity (18.4 dB, IQR 9.21-20.9)
Number of subjects: 30
Study 38016431 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of macular neovascularizations
Number of subjects: 30
Study 38016431 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between square root GA area and visual function tests
Number of subjects: 30
Study 38016468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebroventricular transplantation of allogeneic human neural stem/progenitor cells (hNSCs)
Number of subjects: 15
Study 38016482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pucotenlimab at 200 mg every 3 weeks
Number of subjects: 100
Study 38016718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous trastuzumab (arm A)
Number of subjects: 63
Study 38016718 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (arm B)
Number of subjects: 63
Study 38016718 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 63
Study 38016950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 1500 mg twice daily
Number of subjects: 20
Study 38016950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 38016958 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP users (n=24)
Number of subjects: 48
Study 38016958 — intervention group
Group type: COMPARATOR
Intervention: Non-PrEP users (n=24)
Number of subjects: 48
Study 38017103 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with normal karyotype, FLT3-ITD, DNMT3A, NPM1, and WT1 mutations
Number of subjects: 1726
Study 38017103 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with complex karyotype, ASXL1, SRSF2, U2AF1, RUNX1, or KIT mutations
Number of subjects: 1726
Study 38017103 — intervention group
Group type: EXPERIMENTAL
Intervention: Women in the 2022 European LeukemiaNet intermediate-risk group
Number of subjects: 1726
Study 38017103 — intervention group
Group type: EXPERIMENTAL
Intervention: Men in adverse-risk group
Number of subjects: 1726
Study 38017103 — intervention group
Group type: EXPERIMENTAL
Intervention: SF3B1 mutations in patients aged <60 years
Number of subjects: 1726
Study 38017197 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 35
Study 38017197 — intervention group
Group type: COMPARATOR
Intervention: Stepwise increase and decrease in Positive End Expiratory Pressure (STEP)
Number of subjects: 35
Study 38017325 — intervention group
Group type: EXPERIMENTAL
Intervention: EMI-137 (0.09 mg/kg, 0.13 mg/kg, 0.18 mg/kg)
Number of subjects: 14
Study 38017325 — intervention group
Group type: EXPERIMENTAL
Intervention: EMI-137 (0.13 mg/kg)
Number of subjects: 14
Study 38017325 — intervention group
Group type: EXPERIMENTAL
Intervention: EMI-137-guided MFGI
Number of subjects: 14
Study 38017325 — intervention group
Group type: EXPERIMENTAL
Intervention: EMI-137
Number of subjects: 14
Study 38017340 — intervention group
Group type: EXPERIMENTAL
Intervention: IGV-001 (autologous cell product)
Number of subjects: 0
Study 38017340 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 38017388 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric hotlines
Number of subjects: 4137
Study 38017432 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of IL-6 (≥9.5 pg/mL)
Number of subjects: 310
Study 38017432 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 310
Study 38017432 — intervention group
Group type: COMPARATOR
Intervention: Control group (210 controls)
Number of subjects: 310
Study 38017467 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity health coaching intervention
Number of subjects: 290
Study 38017467 — intervention group
Group type: COMPARATOR
Intervention: General healthy aging education program
Number of subjects: 290
Study 38017482 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 461
Study 38017482 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin-saxagliptin
Number of subjects: 461
Study 38017482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461